Medicare AdvantageCoverageHigh impact
MA11.001l, Treatment of Varicose Veins of the Lower Extremities and Perforator Vein Incompetence
Independence Blue Cross·Vascular Surgery, General Surgery, Dermatology·Medical Policy
Effective date
Jan 1, 2026
We identified it
Jun 19, 2026
Summary
Independence Blue Cross Medicare Advantage reissued policy MA11.001l effective 01/01/2026 with expanded coverage for varicose vein treatments. Key changes include: sclerotherapy and cyanoacrylate adhesive now covered for saphenous veins; CPT 36468 reclassified from cosmetic to medically necessary; CPT 36482 and 36483 upgraded from experimental/investigational to medically necessary; S2202 echosclerotherapy upgraded to medically necessary; CPT 37500 deleted; and CPT 37799 added for stab phlebectomy with fewer than 10 incisions.
Action Required
By December 31, 2025: Billing team must update claims processing system to reflect coverage changes for Independence Blue Cross Medicare Advantage plans. SPECIFIC ACTIONS: (1) Stop denying claims for CPT 36468 (spider vein sclerotherapy) as cosmetic—reclassify as medically necessary; (2) Reclassify CPT 36482 and 36483 from experimental/investigational to medically necessary and update authorization rules; (3) Reclassify S2202 (echosclerotherapy) from non-covered to medically necessary; (4) Remove CPT 37500 from any remaining billing templates and system rules for MA plans; (5) Add CPT 37799 to billing software as medically necessary procedure code representing stab phlebectomy with fewer than 10 incisions; (6) Update prior authorization templates to include new medically necessary procedures (UGFS, liquid sclerotherapy, cyanoacrylate adhesive, endovenous mechanochemical ablation). Notify providers and front desk staff of coverage expansion. Review pending and denied claims from 01/01/2026 forward for potential reprocessing under new coverage rules. Failure to implement changes will result in incorrect denials for covered services and revenue loss.